10 pending office actions • 2 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Kite Pharma, Inc. | 9 |
| Kite Pharma, Inc. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19044010 | METHODS AND SYSTEMS FOR SCHEDULING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE | Kite Pharma, Inc. | SANGHERA, STEVEN G.S. | 3684 | Non-Final OA | Feb 03, 2025 |
| 18531896 | FLOW CYTOMETRIC METHOD FOR CHARACTERIZATION OF T-CELL IMPURITIES | Kite Pharma, Inc. | STONEBRAKER, ALYSSA RAE | 1642 | Non-Final OA | Dec 07, 2023 |
| 18496588 | FACTORS FOR OPTIMIZING IMMUNOTHERAPY | Kite Pharma, Inc. | DAUNER, JOSEPH G | 1682 | Non-Final OA | Oct 27, 2023 |
| 18455028 | IMMUNE CELL FUNCTION | Kite Pharma, Inc. | ALDARONDO, DASIA ALI | 1647 | Non-Final OA | Aug 24, 2023 |
| 18330962 | METHODS OF PREPARING LYMPHOCYTES FOR CELL THERAPY | Kite Pharma, Inc. | ALDARONDO, DASIA ALI | 1647 | Non-Final OA | Jun 07, 2023 |
| 18327651 | CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF | Kite Pharma, Inc. | NGUYEN, QUANG | 1631 | Non-Final OA | Jun 01, 2023 |
| 17816076 | MONITORING AND MANAGEMENT OF CELL THERAPY-INDUCED TOXICITIES | Kite Pharma, Inc. | FRITCHMAN, REBECCA M | 1758 | Non-Final OA | Jul 29, 2022 |
| 17814811 | SPLIT CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE | Kite Pharma, Inc. | HECK, BRYAN WILLIAM | 1643 | Final Rejection | Jul 25, 2022 |
| 17675294 | IMMUNOTHERAPIES | Kite Pharma, Inc. | DONOGHUE, BRITTNEY ERIN | 1675 | Final Rejection | Feb 18, 2022 |
| 16969127 | MODIFIED PLURIPOTENT STEM CELLS AND METHODS OF MAKING AND USE | Kite Pharma, Inc. | ROGERS, ERIC JASON | 1638 | Non-Final OA | Aug 11, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial